Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 2024
March 28 2024 - 8:30AM
Business Wire
Crown Bioscience, a global contract research organization (CRO)
and a JSR Life Sciences company, will showcase significant
contributions in preclinical and translational oncology research at
the American Association for Cancer Research (AACR) 2024 meeting.
Highlighting its latest research, the company will present ten
posters covering a broad spectrum of data from the company's
R&D program.
The data presented will cover a range of innovative techniques
in oncology and immuno-oncology drug discovery and development.
Posters featured at AACR include:
- The in-depth Characterization of Acute Myeloid Leukemia
Patient-Derived Xenograft (PDX) Models with Hotspot Gene Mutations
for Therapeutic Evaluation.
- The development of an Integrated Pipeline for
Immuno-Oncology Drug Testing, using patient-derived tumor
organoids with a reconstituted tumor microenvironment and fresh ex
vivo patient tissue cultures, aiming to enhance therapeutic
evaluation and drug development efficiency with translational
patient-derived systems.
- The utilization of Large Panel Organoid Drug Testing
Combined with Biomarker Analysis, set to deliver insights into
mechanisms of action and boost efficiency within the drug
development pipeline.
- Research on KRAS Inhibitors and PARP
Inhibitor-Induced Resistant PDX Ovarian Cancer Models further
expands on the knowledge base of drug resistance patterns in cancer
while also assessing innovative therapeutic approaches for
targeting mutated tumors, including combination therapy.
- SynAI, an adaptive AI-driven platform for in silico drug
synergism screening, optimizes the exploration of compound
interactions in early-stage cancer drug development.
- Magnetic Resonance Imaging and Bioluminescence Imaging for
Evaluating Tumor Burden in Orthotopic Glioblastoma, merging
digital technology with cancer research to forecast a new era of
therapeutic strategy development.
Abstracts for all ten poster presentations can be found on a
dedicated page, Crown Bioscience AACR posters 2024. Following the
show, all will be available for download.
Attendees are encouraged to visit Booth #1717 to learn
more about these studies and talk to Crown Bioscience’s scientists
to gain deeper insights into the platforms and services on offer to
advance oncology research.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global
Contract Research Organization (CRO) partnering with biotech and
pharmaceutical companies to rapidly advance the discovery and
development of oncology drugs. As the exclusive preclinical CRO
providing tumor organoid services with the well-established
Hubrecht Organoid Technology, we offer over 600 organoid models
spanning 22 cancer indications. Furthermore, we have developed the
world’s largest commercially available PDX collection. Our focus on
helping our customers develop novel therapies aims to ensure that
patients receive the right treatment at the right time. Founded in
2006, we have 13 facilities across the US, Europe, and Asia. For
more information, please visit www.crownbio.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328082232/en/
Crown Bioscience Sarah Martin-Tyrrell pr@crownbio.com